Stockreport

ArriVent BioPharma Reports Third Quarter 2025 Financial Results

ArriVent BioPharma, Inc.  (AVBP) 
PDF Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received FDA IND clea [Read more]